Squamous cell carcinoma of the pancreas: A systematic review and pooled survival analysis |
| |
| Institution: | 1. Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece;2. Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;3. Institute of Liver Studies, King''s College Hospital, London, UK;4. School of Medicine, La Sapienza University of Rome, Rome, Italy;5. HIPON European Commission Educational E-learning Project, Greece;6. Cytopathology Department, Hygeia Hospital, Athens, Greece;1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;2. Center for Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;3. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;4. Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;5. Department of Medical Oncology and Cancer Genomics, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands;6. Immunology and Cutaneous Oncology Programs, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;1. Department of Surgery, Catharina Hospital, PO Box 1350, 5602 ZA, Eindhoven, The Netherlands;2. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), PO Box 19079, 3501 DB, Utrecht, The Netherlands;3. Department of Public Health, Erasmus Medical Centre, PO Box 2040, 3000 CA, Rotterdam, The Netherlands;4. Department of Surgery, Aarhus University Hospital, Norrebrogade 44, DK-8000, Aarhus, Denmark;5. Department of Surgery, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands;6. Department of Surgery, Sint Antonius Hospital, PO Box 2500, 3430 EM, Nieuwegein, The Netherlands;7. Department of Surgery, Erasmus Medical Centre, PO Box 2040, 3000 CA, Rotterdam, The Netherlands;8. Department of Surgery, University Medical Centre Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands;9. Department of Gastroenterology and Hepatology, Antoni van Leeuwenhoek Hospital, PO Box 90203, 1006 BE, Amsterdam, The Netherlands;10. Department of Surgery, University Medical Centre Utrecht, PO Box 85500, 3508 GA, Utrecht, The Netherlands;11. Department of Surgery, VU University Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands;12. Department of Surgery, Antoni van Leeuwenhoek Hospital, PO Box 90203, 1006 BE, Amsterdam, The Netherlands;13. Department of Medical Oncology, Academic Medical Centre, PO Box 22660, 1100 DD, Amsterdam, The Netherlands;14. Department of Surgery, Academic Medical Centre, PO Box 22660, 1100 DD, Amsterdam, The Netherlands;1. Department of Internal Medicine, VieCuri Medical Centre, Venlo, The Netherlands;2. Department of Internal Medicine, Division of Gastroenterology and Hepatology, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands;3. Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands;4. Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands;5. Department of Internal Medicine, Division of Gastroenterology and Hepatology, NUTRIM – School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands;6. PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands;7. Department of Research, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands;8. Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacology, Utrecht University, Utrecht, The Netherlands;9. Department of Central Hospital Pharmacy, VieCuri Medical Centre, Venlo, The Netherlands;10. Department of Internal Medicine, Máxima Medical Centre Eindhoven, Eindhoven, The Netherlands;11. Department of Internal Medicine, Division of General Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands;12. Department of Health Services Research, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre+, Maastricht, The Netherlands;13. MRC Life-course Epidemiology Unit, University of Southampton, Southampton, United Kingdom;14. Department of Epidemiology, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands;15. Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, The Netherlands;1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden;2. Danish Cancer Society, Copenhagen, Denmark;3. Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway;4. Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki, Finland;5. Department of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway;6. Department of Documentation & Quality, Danish Cancer Society, Copenhagen, Denmark;7. Department of Cancer Prevention & Information, Danish Cancer Society, Copenhagen, Denmark;8. Icelandic Cancer Registry, Reykjavik, Iceland;9. Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland;10. Faculty of Social Sciences, University of Tampere, Tampere, Finland;11. Department of Clinical Neuroscience, Division of Insurance Medicine, Karolinska Institutet, Stockholm, Sweden;1. Department of Medical Oncology, Institut Bergonié, 229 Cours de L''Argonne, 33076 Bordeaux, France;2. Department of Pathology, Institut Bergonié, 229 Cours de L''Argonne, 33076 Bordeaux, France;3. National Institute of Health and Medical Research, INSERM U1218, Institut Bergonié, Bordeaux, France;1. Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center, 3855 Health Sciences Drive, La Jolla, CA 92093, USA;2. Caris Life Sciences, 4750 South 44th Place, Phoenix, AZ 85040, USA |
| |
| Abstract: | The diagnosis and treatment of squamous cell carcinoma of the pancreas pose dilemmas in the clinical practice. The present study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to 30th April 2016. A pooled Cox regression analysis was performed to evaluate factors potentially associated with overall survival (OS) and relapse-free survival (RFS). Fifty-four cases of pure squamous cell pancreatic carcinomas were identified in total. The mean age was 61.9 years, and most patients were males (61.1%). The median OS was 7 months. Resectability (p = 0.003) and more recent publication year (p < 0.001) were associated with better OS, as was low/intermediate tumour grade (p = 0.032) with RFS. Despite its poor prognosis, survival rates of pancreatic squamous cell carcinoma seem improved during the recent years; resectability and low/intermediate grade emerged as favourable prognostic factors. Collaborative epidemiological studies are deemed necessary to further validate the results stemming from the published case reports of this rare entity. |
| |
| Keywords: | Squamous cell Pancreatic cancer Systematic review Pooled analysis Survival |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
